All News
Galloway et al report OCP/HRT use in RA is not associated with VTE in UK population based study. Increased risk by having RA, HR 1.52. Risk OCP HR 1.43, HRT HR 2.32 - neither statistical significant but very wide CI's! Hmm... @RheumNow #ACR24 Abstr#0134 https://t.co/CZNoRfYWe8 https://t.co/uC6jA9lcX9
Links:
Richard Conway RichardPAConway ( View Tweet)
Dhir et al. RCT of increasing folic acid from 5-10mg per week to 15-35mg per week if MTX intolerance. No benefit! Although significant placebo response and folic acid is relatively benign. @RheumNow #ACR24 Abstr#0525 https://t.co/D3yfV6a8t6 https://t.co/QpDa1alvMz
Links:
Richard Conway RichardPAConway ( View Tweet)
Courvoisier et al. JAK-pot study analysis. Which therapies work quicker in RA? JAKi (as expected) and TNFi (what!?) faster than IL6 and abatacept. @RheumNow #ACR24 Abstr#0501 https://t.co/7DPPwHlqpP https://t.co/3mOJ62hZhp
Links:
Richard Conway RichardPAConway ( View Tweet)
Serrano-Combarro et al. Abatacept in RA-ILD. 343 patients. In 23.3% ILD progressed on abatacept. Is that good or bad? We need comparative studies! @RheumNow #ACR24 Abstr#0475 https://t.co/nUEDdjGguA https://t.co/sXEF72MafK
Links:
Richard Conway RichardPAConway ( View Tweet)
Serrano-Combarro et al. Baricitinib in RA-ILD . 72 patient case series. PFTs in picture. HRCT stable/improved in 72% over 24 months. Dyspnoea stable/improved in 90%. @RheumNow #ACR24 Abstr#0476 https://t.co/aVI2kRZkMN https://t.co/4l5GKsFKtm
Links:
Richard Conway RichardPAConway ( View Tweet)
#0066
🧬Epigenetics, Gut Microbiota & RA
🔬 110 RA patients v 110 controls
🦠 Collinsella abundance a/w DNA methylation changes (PRHOXNB, TBC1D22A) in RA, correlating with disease activity.
💡❔Role of gut microbiota & epigenetic markers as RA biomarkers
#ACR24 @RheumNow https://t.co/yZn0KkRpE6
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Is biologic response different in men vs women with axSpA?
A Meta-analysis of 11 studies including 11,199 axSpA pts evaluated sex-related response to bDMARDs
-Male pts more likely to achieve BASDAI 50 and ASDAS low disease activity responses compared to females.
#Abst0599… https://t.co/FopBLS4bF6 https://t.co/PpoZB9HwZN
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Dunn et al. Are the medications recommended for RA-ILD by the ACR guidelines used in the real-world. NO! 4108 RA-ILD patients. Only 12% on one of the first line recommended therapies! @RheumNow #ACR24 Abstr#0214 https://t.co/OzW90OA1Vd https://t.co/S1MKmEDrLF
Links:
Richard Conway RichardPAConway ( View Tweet)
Cool data from the JAK-POT study
Have heard JAKs faster than TNF; perhaps not the case!
If anything, TNFs outperformed the others in this study
Trying not to over-read this, but supports my re-emerging preference for TNF
#ACR24 @rheumnow Abstr#0501 https://t.co/NDyPwju3ds
Links:
Mike Putman EBRheum ( View Tweet)
#0513
🔬 Rituximab in RA: IgG levels & infection
➡️ 164 patients (mean age 59, IgG 14g/L, dx duration 13yrs)
🧬 IgG levels ⬇️over time (6 years/25 infusions)
⚠️ Infection-related hospitalizations peaked year 1 ⬆️risk w/ concurrent steroid(HR 2.1,p=0.002)
#ACR24 @RheumNow
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Older adults with RA receive less DMARDs, the standard of care. Dr. Bruno Fautrel shows TOC tolerance in older adults is comparable to younger patients. Let's treat the patient, not their age! #ACR24 @RheumNow ABST#0516 https://t.co/054RWGh3a7
Jiha Lee JihaRheum ( View Tweet)
#0456📱 Digital Health & RA ePROs
💻Rx response in 150 RA patients using ePROs & actigraphy
🔍Actigraphy slightly improved accuracy (86% precision, 83% v. 75% recall with ePROs alone)
💡Passive actigraphy can help classify response &⬇️ ePROs, patient burden.
#ACR24 @RheumNow
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
#0477 🌍 Global prevalence of RA-ILD
➡️21.38% (95% CI 0.15 - 0.29),33 studies, n=14,281
🔬 Higher RA-ILD risk in smokers, low-income regions, DMARD use.
⛔️Wide CI = heterogeneity main limitation
💡 Screening & lifestyle changes key for high-risk groups.
#ACR24 @RheumNow
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
#0501
💥 JAKi & TNFi show faster short-term RA improvement (3months) compared to IL-6i & ABA
➡️n=9590(3049 JAKi, 4606 TNFi, 1284 IL-6, 651 ABA), 14 registers
🕒 JAKi, TNFi improved CDAI, pain, function in 1st two months then stabilised
💡Long-term data needed #ACR24 @RheumNow https://t.co/4yzeAAkGjq
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Which immunomodulators dampen recombinant zoster vaccine immunogenicity?
In this 🇧🇷 study in autoimmune dx patients, overrepresented in non-responders are:
- rituximab pts
- 'combined therapy'
strategies needed for them
but reassuring for the others!
#ACR24 ABST0248 @RheumNow https://t.co/he1ICa9WZg
David Liew drdavidliew ( View Tweet)
#Frailty leads to poor outcomes and occurs earlier in RA patients. Different tools measure frailty as a phenotype vs. deficit accumulation.
Discover the role of frailty in ED from #LancetRheum Ageing Series by Drs. Sarah Lieber and @KWyshamMD !
#ACR24 @RheumNow ABST#1334 https://t.co/25XQBDQMCo
Jiha Lee JihaRheum ( View Tweet)
Poster#0035
🚨Postpartum RA Risk & Mucosal Immunity
👩🍼Elevated anti-CCP-IgG in cervicovaginal fluid of postpartum women (n=25) vs. controls.
🧪Local anti-CCP production despite negative serum
❓Childbirth-associated mucosal inflammation may drive RA onset.
#ACR24 @RheumNow https://t.co/plvtyJDSY1
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Mycophenolate isn't great for vaccine immunogenicity, but withholding MMF for one week after both doses of recombinant zoster vaccine boosts Ab titres ++ in this Brazilian RCT.
A week off post-vaccine: definitely worth considering in stable disease
#ACR24 ABST0247 @RheumNow https://t.co/lajS5DzRbD
David Liew drdavidliew ( View Tweet)
It's been a wild ride over the last 20 years of RA b/tsDMARDs, and fascinating to see how our prescribing habits have changed over that time.
MarketScan data tell a story of fashion and fame. What will the next 20 years be like?
#ACR24 ABST0509 @jeffsparks @RheumNow https://t.co/wCcWgkHrvc
David Liew drdavidliew ( View Tweet)
#ACR24 Ab#0771
ARID5B - transcription factor controls pathologic inflammatory fibroblast
ARID5B: RA risk locus on GWAS, also link to SLE, Graves
Binds to histone editors to epigenetically regulate fibroblast state
ARID5B deletion incr inflamm response, overexpr decr
@RheumNow https://t.co/ebKnX1uTuO
Links:
Eric Dein ericdeinmd ( View Tweet)
